Radar · Life Sciences in New Jersey
Best Life Sciences Companies in New Jersey, United States
The 597 best Life Sciences companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Castle Creek Pharma.
By Riya SenguptaFinancials
597companies tracked
$10.1Bdisclosed funding
1unicorns
238have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × NEW JERSEY
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
330kcombined LinkedIn audience
58%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Insmed Developer of small molecule inhibitors for rare lung diseases 90Tech top 12%Funding top 18%Patents top 20%Market top 24% All 12 signals ▾Techtop 12% Fundingtop 18% Patentstop 20% Markettop 24% Moattop 24% Innovationtop 25% Producttop 28% Growthtop 33% Fin. healthtop 33% Newstop 40% Globaltop 42% Talentbottom 49% Tech: 63 technologies across 7/8 capability areas · Cloud: Cloudflare, Google Cloud Funding: Raised $452M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $452M | 13 mo ago | 912 912 → 1,735 (+90%) · sector median +15% | Will Lewis CEO | WordPressApple iCloud MailMySQL+37 | 636 patents Pulmonary anti-infective drug formulations and DPP1 inhibitor therapeutics | 1 internship |
| 2 | Impulse Dynamics Provider of implantable device for treatment of chronic heart failure 40Funding top 13%Moat top 31%Product top 34%Tech top 49% All 10 signals ▾Fundingtop 13% Moattop 31% Producttop 34% Techtop 49% Patentsbottom 49% Globalbottom 46% Innovationbottom 45% Marketbottom 41% Growthbottom 38% Newsbottom 27% Funding: Raised $443M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $443M | 6 mo ago | 36 | — | WordPressMySQLPHP+24 | 18 patents Implantable cardiac muscle stimulation devices and protein‑based therapeutic modulation. | — |
| 3 | Celularity Developer of allogeneic cell therapies to treat multiple diseases 67Funding top 18%Patents top 30%Fin. health top 38%Moat top 38% All 11 signals ▾Fundingtop 18% Patentstop 30% Fin. healthtop 38% Moattop 38% Innovationtop 39% Growthtop 39% Newstop 39% Markettop 40% Techtop 48% Talentbottom 49% Globalbottom 40% Funding: Raised $290M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 488 patents matched (strict assignee match) · 135 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $290M | 5 mo ago | 225 225 → 145 (-36%) · sector median +15% | Robert Hariri Chairman & CEO | WordPressMySQLPHP+22 | 488 patents Placental-derived extracellular matrix and engineered immune cell therapies for regenerative medicine | — |
| 4 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 4 mo ago | — | Sandy Mou CEO | GSAPCloudflare Rocket LoaderSwiper+8 | — | — |
| 5 | PTC Therapeutics Developer of small molecule drugs for the treatment of rare diseases | $248M | 37 mo ago | 995 995 → 1,159 (+16%) · sector median +15% | — | WordPressApple iCloud MailMySQL+27 | 1,951 patents Small-molecule therapeutics for neurodegenerative and metabolic genetic disorders | — |
| 6 | Convergent Therapeutics Developer of therapeutics to treat cancer | $130M | 22 mo ago | 4 | Philip Kantoff Co-Founder & CEO | — | — | 1 partnership |
| 7 | Tris Pharma Innovating transformative treatments for ADHD, pain, and CNS disorders | $125M | 33 mo ago | 441 441 → 503 (+14%) · sector median +15% | Ketan Mehta Founder & CEO | WordPressMySQLPHP+21 | 217 patents Controlled-release oral dosage forms, especially extended-release and gastro-retentive systems | 1 partnership |
| 8 | Agile Therapeutics Developer of therapeutics for women healthcare | $124M | 28 mo ago | 19 | Al Altomari Chairman & CEO | — | 160 patents Personalized transdermal/dermal contraceptive drug delivery systems | — |
| 9 | ElectroCore Developer of non-invasive vagus nerve stimulation devices 62Funding top 20%Patents top 20%Product top 24%Innovation top 26% All 12 signals ▾Fundingtop 20% Patentstop 20% Producttop 24% Innovationtop 26% Techtop 42% Talenttop 42% Moattop 43% Fin. healthtop 47% Marketbottom 49% Globalbottom 49% Growthbottom 47% Newsbottom 41% Funding: Raised $121M across 13 rounds · 13 rounds over 14 yrs (0.9/yr) Patents: 518 patents matched (strict assignee match) · 124 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $121M | 8 mo ago | 58 58 → 98 (+69%) · sector median +15% | JP Errico Founder | WordPressMySQLPHP+30 | 518 patents Patents concentrated in health & consumer products | — |
| 10 | Navigator Medicines Developer of biologics for targeted immune regulation and restoration | $100M | 21 mo ago | — | Stefan Thomas CEO | — | — | — |
| 11 | Onkos Surgical Modular segmental solutions (3D printing) for orthopedic procedures 48Funding top 23%Talent top 38%Moat top 43%Innovation top 47% All 9 signals ▾Fundingtop 23% Talenttop 38% Moattop 43% Innovationtop 47% Techtop 47% Patentstop 47% Marketbottom 40% Globalbottom 36% Newsbottom 21% Funding: Raised $72.3M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $72M | 17 mo ago | 77 | Patrick Treacy Co-Founder & CEO | WordPressMySQLPHP+28 | 42 patents Soft-tissue attachment technologies for orthopedic implants and endoprostheses. | — |
| 12 | Interpace Biosciences Provider of molecular diagnostic tests and pathology services for cancer diagnosis | $72M | 20 mo ago | 94 | Thomas Burnell CEO & President | Apple iCloud MailLeafletBootstrap+16 | — | — |
| 13 | Claris Bio Developer of a topical formulation for the treatment of corneal wounds, ulcers, and scars | $57M | 9 mo ago | 4 | Sunil Chauhan Co-Founder | Craft CMSApple iCloud MailPHP+8 | — | — |
| 14 | Cellectar Biosciences Developer of phospholipid drug conjugates (PDC) to treat cancer | $57M | 16 mo ago | 15 15 → 20 (+33%) · sector median +15% | — | BootstrapApache HTTP ServerAmazon Web Services+11 | 128 patents Targeted cancer therapy using phospholipid‑flavagline conjugates and dosing of ether analogs | — |
| 15 | Outlook Therapeutics Developer of antibodies for ophthalmic disorders | $52M | 27 mo ago | 8 | — | DrupalPHPBootstrap+22 | — | 1 launch |
| 16 | Cyclacel Diversified company in fire protection and biopharmaceutical industries | $47M | 11 mo ago | 12 | — | DrupalPHPAmazon Web Services+25 | 8 patents Optimizing nucleoside analog anti‑cancer agents (sapacitabine) and their dosing regimens. | — |
| 17 | GlucoTrack Provider of blood glucose monitor for continuous glucose monitoring | $45M | 22 mo ago | 3 | David Malka Co-Founder | WordPress Block EditorWordPressMySQL+28 | 10 patents Implantable low‑power continuous glucose sensors with rapid response and spinal‑cord stimulation integration | 2 launchs · 1 partnership |
| 18 | Avalon Globocare Developer of diagnostics using exosome technology 21News top 26%Funding top 34%Patents top 45%Growth top 47% All 10 signals ▾Newstop 26% Fundingtop 34% Patentstop 45% Growthtop 47% Innovationbottom 48% Moatbottom 44% Globalbottom 40% Techbottom 36% Fin. healthbottom 26% Marketbottom 22% News: 14 BI events in 12 mo (of 21 tracked, 5 types) · 9 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $36.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $37M | 3 mo ago | 6 | — | BootstrapApache HTTP ServerKlaro+13 | 16 patents Engineered soluble GPCR Fc-fusion proteins and S-layer emulsome delivery systems | — |
| 19 | Epifrontier Developer of epigenetic therapeutics targeting hemoglobinopathies like sickle cell disease | $32M | 2 mo ago | — | Ko Kikuzato Co-Founder | — | — | — |
| 20 | Ensho Therapeutics Developer of oral therapies for patients with inflammatory bowel diseases | $28M | 12 mo ago | — | Neena Bitritto-Garg Founder & Co-CEO | Apache HTTP ServerMicrosoft 365jQuery Migrate+4 | — | — |
| 21 | Cytosorbents Developer of hemoperfusion technology for removing toxins from the blood | $22M | 17 mo ago | 198 198 → 137 (-31%) · sector median +15% | — | WordPressApple iCloud MailMySQL+16 | 216 patents Blood purification sorbents for removing toxins, cytokines, and potassium from plasma | — |
| 22 | DiamiR Developer of minimally invasive diagnostic tests | $22M | 13 mo ago | 13 | — | — | 24 patents miRNA biomarker assays for diagnosing and monitoring neurodegenerative disorders | — |
| 23 | Vinci Pharmaceuticals Developer of a drug delivery technology for ophthalmic diseases | $20M | 5 mo ago | 3 | Philip Gioia Chief Executive Officer | — | — | — |
| 24 | ArrePath Developer of anti-infectives to address antimicrobial resistance (AMR) | $20M | 11 mo ago | 16 | — | WordPressMySQLPHP+15 | 5 patents Computational drug ranking and design of antibacterial small‑molecule therapeutics. | — |
| 25 | NovaFlux Technologies Innovating healthcare through advanced medical device technologies and infection control | $20M | 9 mo ago | — | Mohamed Labib Founder & CEO | WixSentryEnvoy+12 | 77 patents Polymer-based oral care cleaning agents and drug‑release devices for membrane therapies | — |
| 26 | Royal Biologics Innovating orthobiologics and wound care solutions for enhanced healing | $20M | 16 mo ago | 16 | Salvatore Leo CEO | — | 14 patents Autologous bone graft enhancement and marrow-derived cell/fluid separation technologies. | 2 launchs |
| 27 | Jana Care Provider of mobile-based healthcare diagnostics for diabetes prevention 53Innovation top 27%Funding top 30%Product top 32%Moat top 39% All 8 signals ▾Innovationtop 27% Fundingtop 30% Producttop 32% Moattop 39% Markettop 45% Talentbottom 49% Globalbottom 39% Techbottom 22% Innovation: 3 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.7M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $18M | 3 mo ago | 60 | Anh Hoang Chief Executive Officer | — | — | — |
| 28 | Biotillion Provider of RFID-based sample tracking systems for biobanks | $18M | 15 mo ago | 7 | — | — | 21 patents Cold-chain monitoring and energy‑harvesting RFID tracking for biological sample storage | — |
| 29 | BioIncept Biotechnology firm pioneering regenerative medicine, immune modulation, and reproductive health solutions | $17M | 13 mo ago | — | Jacqueline Barnea Co-Founder & CEO | — | 153 patents Peptide therapeutics and biomarker diagnostics for neurodegeneration, liver disease, and embryo viability | — |
| 30 | Milestone Scientific Developer of computerized drug delivery injection system for dental and medical purposes | $17M | 1 mo ago | 20 | — | Cart FunctionalityWooCommerceWordPress+37 | 236 patents Precision needle and catheter guidance systems for anesthetic delivery | — |
| 31 | Tevogen Bio Developer of T-cell therapies for viral diseases and cancers | $16M | 16 mo ago | 26 | Ryan Saadi Md Mph Chair and Chief Executive Officer | WordPress Block EditorWordPressApple iCloud Mail+25 | — | — |
| 32 | Protega Pharmaceuticals Provider of specialty pharmaceutical company that focuses on responsible pain management | $16M | 14 mo ago | — | Stefan Aigner CEO | — | — | — |
| 33 | Chemo Mouthpiece Developer of a cryotherapy device to cool the entire oral cavity | $15M | 19 mo ago | 5 | David Yoskowitz Founder & CEO | WordPressMySQLPHP+22 | — | 1 partnership |
| 34 | Kayothera Developer of enzyme therapy for cancer treatment | $14M | 14 mo ago | 2 | Mark Esposito Founder & CSO | — | 23 patents Design of heterocyclic aldehyde dehydrogenase inhibitor compounds for therapeutic use. | — |
| 35 | JOGO Developer of digital therapeutics for neuromuscular conditions | $12M | 12 mo ago | 2 | Sanjai Murali Founder & CEO | Wix eCommerceWixSentry+16 | — | — |
| 36 | Ascendia Pharmaceuticals Provider of specialty pharmaceutical products | $10M | 20 mo ago | 67 | — | — | — | — |
| 37 | Snorble Manufacturer of interactive screen free educational devices for young children | $10M | 18 mo ago | 20 | Mike Rizkalla Co-Founder & CEO | Cart FunctionalityShopifyYouTube+21 | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 38 | LibAirty Provider of airway clearance system synchronizing controlled breathing with chest compressions 24Funding top 50%Talent bottom 49%Global bottom 36% All 3 signals ▾Fundingtop 50% Talentbottom 49% Globalbottom 36% Funding: Raised $9.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $9M | 3 mo ago | — | Anat Shani CEO | — | — | — |
| 39 | Aquestive Therapeutics Developer of small molecule-based therapeutics for the treatment of CNS diseases | $9M | 10 mo ago | 285 285 → 151 (-47%) · sector median +15% | Daniel Barber Chief Executive Officer | DrupalApple iCloud MailMicrosoft 365+22 | 213 patents Advanced epinephrine drug delivery systems and precision oral/topical film dosage forms | 4 job openings |
| 40 | Audicus Online platform offering hearing Aids | $9M | 21 mo ago | 58 | Patrick Freuler Founder & CEO | Cart FunctionalityBigCommerceUnbounce+29 | 2 patents Audiology hearing test devices and diagnostic hearing assessment systems | 1 job opening |
| 41 | TAXIS Pharma Biotech combating antimicrobial resistance through innovative therapies and novel mechanisms | $8M | 12 mo ago | 6 | Gregory Mario CEO | WordPressMySQLPHP+18 | — | — |
| 42 | Advanced Tactile Imaging Innovating women's pelvic healthcare with biomechanical mapping and digital twin technologies 16Innovation top 40%Funding top 43%Talent bottom 45%Product bottom 44% All 7 signals ▾Innovationtop 40% Fundingtop 43% Talentbottom 45% Productbottom 44% Globalbottom 29% Techbottom 24% Marketbottom 13% Innovation: 2 product lines Funding: Raised $6.3M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $6M | 10 mo ago | 6 | Vladimir Egorov Chairman and Chief Executive Officer | — | — | — |
| 43 | Atux Iskay Developer of small molecule modulators of Protein Phosphatase 2A | $5M | 15 mo ago | — | Michael Ohlmeyer Founder | — | 20 patents Medicinal chemistry of diaryl‑substituted tetrahydropyran and methylene scaffolds for therapeutic agents | — |
| 44 | Flyway Health Provider of AI agents for healthcare data analysis and strategy | $4M | 7 mo ago | — | Taylan Aydın Co-Founder & CTO | — | — | — |
| 45 | CorFigo Developer of a trans-pericardial tissue ablation device | $2M | 6 mo ago | 4 | Deron Siddons Co-Founder & CEO | — | 34 patents Cryogenic cooling systems and directional tissue ablation devices for medical procedures | — |
| 46 | Sentrimed Developer of precision oncology therapeutics | $2M | 1 mo ago | — | Bill Ragatz President and CEO | — | 2 patents Patents concentrated in health & consumer products | — |
| 47 | Origami Surgical Developer of robotic-assisted surgery devices for surgeons | $1M | 11 mo ago | 5 | Patrick Culligan Founder / CMO | — | — | — |
| 48 | NeuroTechR3 Developing personalized neurorehabilitation exergames | $1M | 12 mo ago | 8 | Amanda Gross Co-Founder & CTO | — | — | 1 internship |
| 49 | Link Biosystems Developer of human pre‑clinical models and micro‑physiological systems for cancer drug development | $1M | 12 mo ago | — | Kacey Ronaldson-Bouchard Co-Founder & Chief Scientific Officer | — | — | — |
| 50 | Rhizome AI Provider of regulatory affairs search tool for FDA and EMA data | $585K | 5 mo ago | — | Doug Mead Co-Founder | — | — | — |
Top 12 Life Sciences companies in New Jersey
#1
Series F · Marlton, New Jersey · founded 1998 · 36 employees$443.1Mraised▾
Series F · Marlton, New Jersey · founded 1998 · 36 employees
Impulse Dynamics is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed, Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer is CE is FDA approved.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 13%Moat
top 31%Product
top 34%Tech
top 49%Patents
bottom 49%Global
bottom 46%Funding: Raised $443M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series F (Dec 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 18 patents · Soonicorn
Product: 1 distinct product line · Company stage: Series F
Audience (LinkedIn): 14k LinkedIn followers — 4.4% of this cohort's audience
Funding rounds
- Dec 2025Series F$158M
- Feb 2025Unattributed$84.1M
- Feb 2024Series E$136.5M
- Jul 2023Series E$91.4M
Investors
Redmile Group, Perceptive Advisors, Alger, Hobart Healthcare, Goldstone Investment, Abiomed
Tech stack
Animate.CssAzureChart.JsDiviFlywheelFont Awesome
#2
Public · Warren, New Jersey · founded 2016 · 225 employees$290Mraised▾
Public · Warren, New Jersey · founded 2016 · 225 employees
Developer of allogeneic cell therapies to treat multiple diseases. The company focuses on placenta-derived cell therapy product candidates for cancer, infectious diseases, and degenerative diseases. The company's lead candidate is CYNK001 for acute myeloid leukemia and Glioblastoma.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 18%Patents
top 30%Fin. health
top 38%Moat
top 38%Innovation
top 39%Growth
top 39%Funding: Raised $290M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Post IPO (Dec 2025)
Patents: 488 patents matched (strict assignee match) · 135 filings since 2022 vs 309 in 2017-21 · Latest publication 2026
Fin. health: Revenue ~$54.2M (FY2024) · Net margin -345.4% · Revenue +138% YoY
Audience (LinkedIn): 17k LinkedIn followers — 5.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. Celebrative) announced in 12 mo
Funding rounds
- Dec 2025Post IPO$10M
- Oct 2025Post IPO$2M
- Jul 2025Post IPO$2M
- Jul 2025Post IPO$1M
Founders & team
Investors
Sorrento Therapeutics, United Therapeutics, Human Longevity, Celgene, Genting Group, Section 32
Tech stack
CloudflareCloudflare Bot ManagementDocusignFlickityGodaddyGoogle Analytics
#3
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Series D · Berkeley Heights, New Jersey · founded 2019
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Jan 2026Series D$287M
Founders & team
Investors
SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCloudflare Rocket LoaderGoogle Font ApiHstsHttp/3
#4
Public · Freehold, New Jersey · founded 2016 · 6 employees$36.7Mraised▾
Public · Freehold, New Jersey · founded 2016 · 6 employees
Avalon GloboCare is involved in developing exosome technology. They have developed core platforms, namely Avalon Cell and Avalon Rehab for early detection of oral cancer (saliva exosomes), ovarian cancer (plasma exosomes), kidney cancer (urine exosomes), skin regeneration, anti-fibrosis, treatments of degenerative disorders such as Alzheimer’s disease, arthritis, osteoporosis, etc.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
News
top 26%Funding
top 34%Patents
top 45%Growth
top 47%Innovation
bottom 48%Moat
bottom 44%News: 14 BI events in 12 mo (of 21 tracked, 5 types) · 9 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: M&A, Announcements, Acquisition
Funding: Raised $36.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Post IPO (Feb 2026)
Patents: 16 patents matched (strict assignee match) · 8 filings since 2022 vs 8 in 2017-21 · Latest publication 2024
Funding rounds
- Feb 2026Post IPO$3.2M
- Oct 2023Post IPO$700K
- Dec 2022Post IPO$4M
- Sep 2019Conventional Debt$20M
Investors
Falcon Capital, PagodaTree Partners
Tech stack
Apache Http ServerBootstrapCore-JsFacebook PixelFancyboxGodaddy
#5
Public · Basking Ridge, New Jersey · founded 2005 · 58 employees$121.4Mraised▾
Public · Basking Ridge, New Jersey · founded 2005 · 58 employees
Developer of non-invasive vagus nerve stimulation devices. The company has developed gammaCore a hand-held portable device that produces a mild electrical signal to treat migraines and cluster headaches. It is also, used for epilepsy, gastric motility disorders, depression, and anxiety.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 20%Patents
top 20%Product
top 24%Innovation
top 26%Tech
top 42%Talent
top 42%Funding: Raised $121M across 13 rounds · 13 rounds over 14 yrs (0.9/yr) · Last round Post IPO (Oct 2025)
Patents: 518 patents matched (strict assignee match) · 124 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Product: 2 distinct product lines · Company stage: Public
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$1.9M
- Jun 2024Post IPO$7.8M
- Aug 2023Post IPO$750K
- Oct 2021Post IPO$192K
Founders & team
Investors
Core Ventures Group, Merck Global Health Innovation Fund, American Investment Holdings, Knoll Capital Management, Easton Capital Investment Group, avenuealtd.com
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Ses
#6
Funding Raised · Pennington, New Jersey · founded 2025$32Mraised▾
Funding Raised · Pennington, New Jersey · founded 2025
Developer of epigenetic therapeutics targeting hemoglobinopathies like sickle cell disease. The company is creating oral therapies designed to increase fetal hemoglobin. Its lead program focuses on sickle cell disease, with potential expansion to other conditions. The goal is to provide accessible treatments worldwide, especially in resource-limited regions.
Funding rounds
- Mar 2026Grant (prize money)$32M
Founders & team
Investors
Amed
#7
Public · Livingston, New Jersey · founded 1989 · 20 employees$16.6Mraised▾
Public · Livingston, New Jersey · founded 1989 · 20 employees
Developer of computerized drug delivery injection system for dental and medical purposes. It offers a CompuFlo system, a computer-controlled drug delivery system for epidural punctures that works using dynamic pressure sensing technology. The CathCheck system confirms the placement of the catheter and the Single Tooth Anesthesia system instrument is a computer-assisted system for local anesthesia.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Apr 2026Post IPO$2.1M
- Jul 2015Grant (prize money)$1.5M
- May 2014PE$10M
- Mar 2005Post IPO$3M
Investors
NCBiR
Tech stack
AkismetAlpine.JsAosCart FunctionalityCdnjsCloudflare
#8
Series C · Newton, New Jersey · founded 2011 · 60 employees$17.7Mraised▾
Series C · Newton, New Jersey · founded 2011 · 60 employees
JanaCare is a healthcare technology startup providing a diagnostic device and a mobile-based platform for diabetes management. The device can measure blood glucose, lipids, creatinine, and hemoglobin. Its Habits program available both on the web and through a mobile application is based on the diabetes prevention program curriculum. The mobile app "food: habits" tracks user's calories and fat intake provides suggestions for meals, aids to set calorie burning and weight loss goals.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Innovation
top 27%Funding
top 30%Product
top 32%Moat
top 39%Market
top 45%Talent
bottom 49%Innovation: 3 product lines · Deep-tech classification: Tech Hardware
Funding: Raised $17.7M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Series C (Mar 2026)
Product: 3 distinct product lines · 3 published apps (40.5k installs) · Company stage: Series C
Funding rounds
- Mar 2026Series C$1.4M
- Mar 2025Series C$2.9M
- Oct 2023Series C$13.1M
- Nov 2022Series B$575.3K
Founders & team
Investors
Department of Biotechnology, IAG Capital Partners, Agent Capital, First Avenue Ventures, Patamar Capital, MK Energy
Tech stack
BootstrapAmazon Web ServicesCloudflareOwl CarouselModernizrJquery
#9
Public · Bridgewater, New Jersey · founded 1999 · 912 employees$452.2Mraised▾
Public · Bridgewater, New Jersey · founded 1999 · 912 employees
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Tech
top 12%Funding
top 18%Patents
top 20%Market
top 24%Moat
top 24%Innovation
top 25%Tech: 63 technologies across 7/8 capability areas · Cloud: Cloudflare, Google Cloud · Devops: Nginx
Funding: Raised $452M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Grant (prize money) (Apr 2025)
Patents: 636 patents matched (strict assignee match) · 231 filings since 2022 vs 248 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 77k LinkedIn followers — 23.3% of this cohort's audience
Funding rounds
- Apr 2025Grant (prize money)$1.7M
- Jan 2018Post IPO$450M
- Dec 2010Grant (prize money)$489K
Founders & team
Investors
United States Department of Agriculture, HHS, Bessemer Venture Partners, Ridgeback Capital Management, Foresite Capital, Intersouth Partners
Tech stack
ApolloApple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyes
#10
Series A · Jersey City, New Jersey · founded 2018 · 4 employees$57Mraised▾
Series A · Jersey City, New Jersey · founded 2018 · 4 employees
Developer of a topical formulation for the treatment of corneal wounds, ulcers, and scars. It uses research based on hepatocyte growth factor (HGF) to promote healing that aims to restore corneal structure and function in serious conditions.
Funding rounds
- Sep 2025Conventional Debt$2.3M
- Feb 2025Conventional Debt$3.3M
- Dec 2023Series A$44.5M
Founders & team
Investors
Novo Holdings, RA Capital Management, Mass General Brigham Ventures, Chasing Science
Tech stack
Apple Icloud MailCraft CmsGodaddyGoogle Font ApiLazysizesNginx
#11
Series B · Monmouth Junction, New Jersey · founded 2019 · 3 employees$20.2Mraised▾
Series B · Monmouth Junction, New Jersey · founded 2019 · 3 employees
Developer of a drug delivery technology for ophthalmic diseases. It offers EPIPLANT a transformative platform technology that provides needle free drug delivery to the retina for patients to focus in ophthalmology on intermediate-stage therapeutics for retinal diseases
Funding rounds
- Jan 2026Series B$20.2M
Founders & team
#12
Series A · Jersey City, New Jersey · founded 2016$9.3Mraised▾
Series A · Jersey City, New Jersey · founded 2016
Provider of airway clearance system synchronizing controlled breathing with chest compressions. The system facilitates controlled breathing at different lung volumes. Airflow is directed to clear small airways. The system is designed to keep lungs clear of mucus build-up and infections. It aims to reduce symptoms with daily sessions. The device is intended to improve respiratory health and quality of life.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 50%Talent
bottom 49%Global
bottom 36%Funding: Raised $9.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series A (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United States)
Funding rounds
- Feb 2026Series A$5M
- Aug 2025Series A$4.3M
Founders & team
Investors
Njeda, Edge Medical Ventures, New Jersey Innovation Evergreen Fund
Funding & investor landscape
$10.1Btotal disclosed funding
248companies funded
991disclosed rounds
3rounds last 90 days
Most active investors
New Enterprise Associates7 rounds
Notable founders
Robert Hariri
Chairman & CEO · Celularity
Sandy Mou
CEO · CORXEL
JP Errico
Founder · ElectroCore
Dan Goldberger
CEO and Director · ElectroCore
Ko Kikuzato
Co-Founder · Epifrontier
Minoru Yoshida
Co-Founder · Epifrontier
Anh Hoang
Chief Executive Officer · Jana Care
Will Lewis
CEO · Insmed
Sunil Chauhan
Co-Founder · Claris Bio
Clarke Atwell
Co-Founder & CEO · Claris Bio
Philip Gioia
Chief Executive Officer · Vinci Pharmaceuticals
Anat Shani
CEO · LibAirty
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share fell from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and fermentation advancements are intensifying simultaneously — papers jumped from 3→62 and 2→54 respectively.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern research is rising sharply — papers tripled from 15 to 45 across U.S. biotechnology institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
How many Life Sciences companies are there in New Jersey, United States?
Radar tracks 597 indexable Life Sciences companies headquartered in New Jersey, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in New Jersey, United States?
The Life Sciences companies in New Jersey, United States on this list have raised a combined $10.1B in disclosed equity funding across 248 funded companies.
Which is the highest-funded Life Sciences company in New Jersey, United States?
Castle Creek Pharma is the highest-funded Life Sciences company in New Jersey, United States, with $663.1M in disclosed equity funding.
How many Life Sciences companies in New Jersey, United States are funded?
248 of the 597 Life Sciences companies in New Jersey, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in New Jersey, United States?
1 Life Sciences company in New Jersey, United States on this list is valued at $1B or more.
Who are the top investors in New Jersey, United States Life Sciences companies?
The most active investors in New Jersey, United States Life Sciences companies on this list include HHS, National Science Foundation, NIH, Foundation Venture Capital Group, Orbimed.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.